Company Filing History:
Years Active: 2019
Title: Ji Hyun Um: Innovator in Blood Cancer Therapeutics
Introduction
Ji Hyun Um is a notable inventor based in South Korea, recognized for his contributions to the field of blood cancer therapeutics. His innovative work focuses on developing oligonucleotide-modified nucleic acids that show promise in treating blood cancer.
Latest Patents
Ji Hyun Um currently holds 1 patents. However, his significant research includes a therapeutic agent for blood cancer. This invention involves an oligonucleotide-modified nucleic acid that contains at least one 1-ß-D-arabinofuranosylcytosine, which has demonstrated therapeutic efficacy. The novel oligonucleotide-modified nucleic acid is rich in guanosine and exhibits excellent apoptotic activities on both blood cancer cells and drug-resistant blood cancer cells. This research aims to provide a composition for preventing, ameliorating, or treating blood cancer, utilizing the oligonucleotide-modified nucleic acid as an active ingredient.
Career Highlights
Ji Hyun Um is associated with Aptabio Therapeutics Inc., where he continues to advance his research in therapeutic agents. His work is pivotal in the ongoing fight against blood cancer, contributing to the development of innovative treatment options.
Collaborations
He collaborates with esteemed colleagues, including Sung Hwan Moon and Soo Jin Lee, who share his commitment to advancing cancer therapeutics.
Conclusion
Ji Hyun Um's innovative research in blood cancer therapeutics highlights his dedication to improving treatment options for patients. His work in developing oligonucleotide-modified nucleic acids represents a significant step forward in the fight against this challenging disease.